Back Home About Us

BHIVA 2017: Despite Reassuring Data, We Can’t Yet Say U=U for Breastfeeding

While effective HIV treatment greatly reduces the risk of onward transmission during breastfeeding, it does not appear that the risk is zero, a leading pediatrician told the British HIV Association (BHIVA) conference last month in London last week.

alt

Read more:

FDA Approves Juluca Dual Single-Tablet Regimen

On November 21, the U.S. Food and Drug Administration approved Juluca, a fixed-dose coformulation containing dolutegravir and rilpivirine, for the treatment of adults with HIV who have undetectable viral load on their current antiretroviral regimen. Juluca, a joint product of ViiV Healthcare and Janssen, is the first complete single-tablet regimen containing only 2 drugs.

alt

Read more:

EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment

HIV maintenance treatment with 2 drugs, a boosted protease inhibitor and lamivudine, is just as effective as 3-drug treatment with a boosted protease inhibitor for people who already have fully suppressed viral load, according to a meta-analysis of clinical trials presented last weekat the 16th European AIDS Conference (EACS 2017) in Milan.

alt

Read more:

EACS 2017: New European Guidelines Cover HIV, Hepatitis C, and Related Conditions

Everyone with HIV and hepatitis C virus (HCV) coinfection should receive direct-acting antiviral therapy for hepatitis C and should receive the same treatment regimens for hepatitis C as people with HCV monoinfection, new European guidelines issued at the 16th European AIDS Conference recommend.

alt

Read more:

EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound

ABX464, a new drug that stimulates the clearance of HIV from infected cells, reduces the reservoir of HIV DNA in the body but does not delay the rebound of viral load when antiretroviral treatment is interrupted, Linos Vandekerckhove of the University of Ghent reported at the 16th European AIDS Conference (EACS 2017) last week in Milan.

alt

Read more:

EACS 2017: Fostemsavir Controls Viral Load in Half of People with Highly Drug-Resistant HIV

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the recent 16th European AIDS Conference in Milan.

alt

Read more:

IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult

For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).

alt

Read more:

Many Americans Still Get HIV Diagnosis Years After Infection, CDC Says

Many people with HIV in the United States are still being diagnosed with HIV late, and therefore are not getting the full therapeutic and prevention benefits of starting antiretroviral therapy (ART) early, according to the latest Vital Signs report from the Centers for Disease Control and Prevention (CDC), released in advance of World AIDS Day.

alt

Read more:

IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference last week in San Diego.

alt

Read more: